Guillain-Barré Syndrome, GBS, is a rare autoimmune disorder in which the body’s immune system attacks the peripheral nerves. First discovered in 1916 by Georges Guillain and Jean Alexandre Barré, it is now the leading cause of acute flaccid paralysis worldwide since polio was largely eradicated. The condition often begins with mild tingling and muscle weakness that progresses rapidly over days to weeks. While GBS occurs in every region of the world, its exact prevalence varies and depends on local infection patterns, diagnostic capacity, and reporting systems. In Nigeria, data on GBS remains limited, making it difficult to state a precise national burden. This essay discusses the nature of GBS, its causes and treatment, and what is currently known about its prevalence in Nigeria.

The Nature and Causes of GBS

GBS is not caused by a single pathogen, but it usually follows an infection. In 60-70% of cases, patients report a respiratory or gastrointestinal illness 1-3 weeks before neurological symptoms appear. The most common trigger globally is _Campylobacter jejuni_, a bacterium spread through undercooked poultry and contaminated water. Other triggers include influenza, Zika virus, dengue, COVID-19, surgery, and, very rarely, certain vaccines. The risk from infection is far higher than the risk from vaccination.

The immune system, while fighting the infection, produces antibodies that mistakenly target gangliosides on the surface of peripheral nerves. This leads to demyelination and nerve dysfunction. The result is ascending weakness: symptoms typically start in the legs and feet, then move upward to the trunk, arms, and facial muscles. Deep tendon reflexes disappear early. In severe cases, about 20-30% of patients develop respiratory muscle weakness and require mechanical ventilation. Autonomic nerve involvement can cause fluctuations in blood pressure, heart rate, and bladder control.

Diagnosis is based on clinical findings, supported by lumbar puncture showing “albuminocytologic dissociation” — high protein with normal cell count — and nerve conduction studies showing slowed signals. Early diagnosis is critical because treatment is most effective when started within 2 weeks of symptom onset.

Treatment and Projections

GBS has no cure, but immune therapy can shorten the course and reduce severity. The two main treatments are intravenous immunoglobulin, IVIG, and plasma exchange. Both work by modulating the abnormal immune response. Supportive care is equally important: monitoring of breathing, heart rhythm, blood pressure, and prevention of complications such as pneumonia, blood clots, and bedsores. Physiotherapy begins early and continues for months as nerves slowly regenerate at 1-2 mm per day.

The prognosis is generally good. About 70-80% of patients regain the ability to walk independently within 6 months. However, 10-20% are left with residual weakness, fatigue, or pain, and mortality is 3-5% even with good care, usually due to respiratory failure or cardiac arrhythmia.

This is general medical information. GBS is a medical emergency. If anyone develops rapidly progressive weakness, difficulty breathing, or trouble swallowing, they should seek care from a qualified healthcare professional or go to the nearest emergency department immediately. Only a doctor can confirm the diagnosis and decide on treatment.

Prevalence of GBS in Nigeria 

Globally, the incidence of GBS is estimated at 1-2 cases per 100,000 people per year. The condition occurs year-round with slight seasonal peaks linked to respiratory and diarrheal infections. 

In Nigeria, the exact prevalence is unknown due to the absence of a national registry and population-based studies. Most available data come from hospital-based case series in tertiary centers such as the University College Hospital Ibadan, Lagos University Teaching Hospital, Aminu Kano Teaching Hospital, and University of Port Harcourt Teaching Hospital. These reports describe GBS as “uncommon but not rare,” with individual centers documenting between 5 and 30 cases over several years.

Several factors suggest the true burden in Nigeria may be higher than reported:

1. Underdiagnosis: Many secondary and primary health facilities lack nerve conduction machines and capacity for lumbar puncture. GBS is often misdiagnosed as stroke, polio, or spiritual illness.

2. Underreporting: GBS is not a notifiable disease in Nigeria. There is no mandatory reporting system like that for polio or Lassa fever.

3. Infectious environment: Nigeria has a high burden of diarrheal diseases and exposure to _Campylobacter_ from water and food. Because _Campylobacter_ is strongly linked to GBS, some neurologists believe Nigeria’s incidence may be at the higher end of the global range, possibly 2-3 per 100,000 per year. This remains an estimate until proper studies are done.

4. Post-outbreak clusters: During outbreaks of meningitis, Lassa fever, and COVID-19, Nigerian hospitals have observed clusters of GBS cases, indicating that infection-driven spikes occur locally.

The Nigeria Centre for Disease Control, NCDC, and neurologists have called for improved surveillance and research to determine the true burden. Until then, GBS in Nigeria is understood through clinical experience rather than national statistics.

Challenges and Recommendations  

The main challenges for GBS management in Nigeria are awareness, diagnosis, and critical care. Public awareness is low, so patients often present late when nerve damage is extensive. Diagnostic tools are concentrated in a few teaching hospitals, leaving rural patients underserved. Intensive care units with ventilatory support are limited, yet they are lifesaving for patients with respiratory failure.

To improve outcomes, three steps are needed. First, health worker and public education on the warning signs of GBS — rapid, ascending weakness and loss of reflexes — can encourage early hospital presentation. Second, expanding access to nerve studies and lumbar puncture, including through telemedicine links to neurologists, would improve diagnosis. Third, establishing a national GBS registry would provide reliable data on prevalence, triggers, and outcomes, helping policymakers plan resources.

Conclusion

Guillain-Barré Syndrome is a serious but treatable neurological emergency that affects only about 14,000 people globally each year. In Nigeria, the true prevalence is not yet known due to gaps in surveillance, diagnostics, and reporting. Hospital data suggest the condition exists in all regions, and its incidence may be influenced by the country’s high burden of infectious diseases. While the outlook for most patients is positive with timely treatment and supportive care, Nigeria must invest in awareness, diagnostic capacity, and data collection to reduce preventable deaths and disability. Ultimately, understanding the real burden of GBS in Nigeria is the first step toward better care for those affected.